These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
370 related items for PubMed ID: 20941510
21. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451 [Abstract] [Full Text] [Related]
22. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. Yonezawa T, Hasegawa S, Asai M, Ninomiya T, Sasaki T, Cha BY, Teruya T, Ozawa H, Yagasaki K, Nagai K, Woo JT. Eur J Pharmacol; 2011 Jan 15; 650(2-3):511-8. PubMed ID: 21047508 [Abstract] [Full Text] [Related]
23. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures. Uchiyama S, Yamaguchi M. Biochem Pharmacol; 2004 Apr 01; 67(7):1297-305. PubMed ID: 15013845 [Abstract] [Full Text] [Related]
24. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells. Ishizuka S, Kurihara N, Miura D, Takenouchi K, Cornish J, Cundy T, Reddy SV, Roodman GD. J Steroid Biochem Mol Biol; 2004 May 01; 89-90(1-5):331-4. PubMed ID: 15225795 [Abstract] [Full Text] [Related]
25. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Koide M, Murase Y, Yamato K, Noguchi T, Okahashi N, Nishihara T. Biochem Biophys Res Commun; 1999 May 27; 259(1):97-102. PubMed ID: 10334922 [Abstract] [Full Text] [Related]
26. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY. J Bone Miner Res; 2006 Oct 27; 21(10):1648-56. PubMed ID: 16995820 [Abstract] [Full Text] [Related]
27. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. Arai A, Mizoguchi T, Harada S, Kobayashi Y, Nakamichi Y, Yasuda H, Penninger JM, Yamada K, Udagawa N, Takahashi N. J Cell Sci; 2012 Jun 15; 125(Pt 12):2910-7. PubMed ID: 22454522 [Abstract] [Full Text] [Related]
28. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells. Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT. J Nat Med; 2012 Jan 15; 66(1):8-16. PubMed ID: 21656335 [Abstract] [Full Text] [Related]
29. Vitamin D and bone. Suda T, Ueno Y, Fujii K, Shinki T. J Cell Biochem; 2003 Feb 01; 88(2):259-66. PubMed ID: 12520524 [Abstract] [Full Text] [Related]
30. Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. Balani D, Aeberli D, Hofstetter W, Seitz M. Arthritis Rheum; 2013 Feb 01; 65(2):436-46. PubMed ID: 23124514 [Abstract] [Full Text] [Related]
31. [RANKL signaling and bone diseases. Quiescent osteoclast precursors and RANKL signaling]. Mizoguchi T. Clin Calcium; 2011 Aug 01; 21(8):1187-92. PubMed ID: 21814024 [Abstract] [Full Text] [Related]
32. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. Ishida M, Amano S. J Bone Miner Metab; 2004 Aug 01; 22(5):415-29. PubMed ID: 15316862 [Abstract] [Full Text] [Related]
33. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. Merle B, Itzstein C, Delmas PD, Chenu C. J Cell Biochem; 2003 Oct 01; 90(2):424-36. PubMed ID: 14505357 [Abstract] [Full Text] [Related]
34. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Kondo H, Guo J, Bringhurst FR. J Bone Miner Res; 2002 Sep 01; 17(9):1667-79. PubMed ID: 12211438 [Abstract] [Full Text] [Related]
36. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Kaji H, Kanatani M, Sugimoto T, Chihara K. Horm Metab Res; 2005 Oct 01; 37(10):589-92. PubMed ID: 16278780 [Abstract] [Full Text] [Related]
37. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Nagai M, Sato N. Biochem Biophys Res Commun; 1999 Apr 21; 257(3):719-23. PubMed ID: 10208850 [Abstract] [Full Text] [Related]
38. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH. Eur J Pharmacol; 2009 Nov 25; 623(1-3):22-9. PubMed ID: 19766111 [Abstract] [Full Text] [Related]
39. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. J Surg Res; 2001 Sep 25; 100(1):18-24. PubMed ID: 11516200 [Abstract] [Full Text] [Related]
40. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A. Murase Y, Okahashi N, Koseki T, Itoh K, Udagawa N, Hashimoto O, Sugino H, Noguchi T, Nishihara T. J Cell Physiol; 2001 Aug 25; 188(2):236-42. PubMed ID: 11424090 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]